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Summary
Pandemics in poultry caused by the highly pathogenic avian influenza (HPAI) A virus occur too
frequently globally, and there is growing concern about the HPAI A virus due to the possibility of
a pandemic among humans. Thus, it is important to develop a vaccine against HPAI suitable for
both humans and animals. Various approaches are underway to develop such vaccines. In
particular, an edible vaccine would be a convenient way to vaccinate poultry because of the
behaviour of the animals. However, an edible vaccine is still not available. In this study, we
developed a strategy of effective vaccination of mice by the oral administration of transgenic
Arabidopsis plants (HA-TG) expressing haemagglutinin (HA) in the endoplasmic reticulum (ER).
Expression of HA in the ER resulted in its high-level accumulation, N-glycosylation, protection
from proteolytic degradation and long-term stability. Oral administration of HA-TG with saponin
elicited high levels of HA-specific systemic IgG and mucosal IgA responses in mice, which resulted
in protection against a lethal influenza virus infection with attenuated inflammatory symptoms.
Based on these results, we propose that oral administration of freeze-dried leaf powders from
transgenic plants expressing HA in the ER together with saponin is an attractive strategy for
vaccination against influenza A virus.
Introduction
Influenza A virus is one of the most serious respiratory pathogens
that cause severe illness and are potentially fatal (Cox et al.,
2004). In recent outbreaks of new swine H1N1 influenza virus,
the virus infected a large number of humans and caused
significant concern as a global pandemic (Garten et al., 2009).
Highly pathogenic avian influenza (HPAI) A virus subtype H5N1,
HPAI A (H5N1), is regarded as being the next global pandemic
threat for humans because these viruses spread easily at the
global level by avian hosts across the species barrier and can
directly infect humans (Munster and Fouchier, 2009; Webster
et al., 2006). Once the virus infects humans, it causes extraor-
dinarily high mortality and shows a high mutation rate (Abdel-
Ghafar et al., 2008). As the first case of human infection with
HPAI A (H5N1) in 1997, 386 deaths of a total of 650 cases of
human infection have been reported (WHO, 2014). Human
infection of HPAI A (H5N1) has been sporadic, but the risk of
human infection is increasing because of wide circulation and
rapid evolution of the virus (Webster and Govorkova, 2006;
Webster et al., 1992). Therefore, there is increasing demand for
HPAI A (H5N1) vaccines to prevent the onset of the pandemic
situation.
The most common method of vaccination against influenza
viruses is parenteral injection. Injectable vaccines induce mainly a
systemic IgG response, but only a little mucosal IgA response which
plays an important role for the protection against respiratory virus
infection (Holmgren and Czerkinsky, 2005). By contrast, mucosal
vaccination provokes both mucosal (Secretory IgA) and systemic
(Serum IgG) immune responses, thus being obviously a better
strategy against respiratory pathogens (Lycke, 2012; Ogra et al.,
2001). Indeed, intranasal vaccination, a type of the main types of
mucosal vaccination, induces strong mucosal immune responses.
However, the intranasal vaccination has potential risk of patients
with asthma or Bell’s palsy which may exacerbate the disease
(Hodge et al., 2001;Mutsch et al., 2004). The oral route is another
choice for the mucosal vaccination. Moreover, oral vaccination is
easier, cheaper and safer than parenteral vaccination and has a
better patient compliance (Mitragotri, 2005).
Many different approaches have been used to produce vaccine
antigens for oral vaccination. These include bacterial fermenta-
tion, insect cell cultures, mammalian cell cultures and plant tissue
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cultures (Chu and Robinson, 2001; Swartz, 2001; Wang et al.,
2006). However, these cell culture–based systems are not feasible
propositions for antigen production in terms of cost, product
quality and safety (Ma et al., 2003). Recently, transgenic plant
systems have been recognized to have many advantages over the
traditional systems (Guan et al., 2013; Streatfield et al., 2001;
Yusibov and Rabindran, 2008): inexpensive and easy handling,
complete exclusion of microbial and animal products by appro-
priately controlling the microbial contamination, potential for
post-translational modifications, long-term storage in transgenic
plants as seeds and most importantly a potential for the oral
administration of edible plant parts without additional processing.
Therefore, the development of a plant-based edible vaccine for
HPAI A (H5N1) has been the subject of great interest as a
preventive measure against influenza pandemics (Streatfield,
2005; Walmsley and Arntzen, 2003).
In this study, we investigated whether haemagglutinin (HA) of
HPAI A (H5N1), expressed in the ER of transgenic Arabidopsis
plants can be used as an edible vaccine. At the same time, we
identified an adjuvant suitable for oral immunization using plant
tissues. From this study, we provide evidence that oral adminis-
tration of freeze-dried leaf powders from plants expressing HA in
the ER together with saponin as an adjuvant induced strong
immune responses that conferred on mice the protective immu-
nity against a lethal avian influenza virus challenge.
Results
Transgenic Arabidopsis plants expressing influenza A
virus haemaggulutinin in the ER
To develop an edible vaccine against avian influenza A virus, we
tested whether haemagglutinin (HA) of the A/Hong Kong/213/03
(H5N1) influenza virus strain expressed in the ER of Arabidopsis
plants is suitable for edible vaccination. We reasoned that the ER
is a suitable location for storing the antigen because proteins can
be N-glycosylated and the ER membrane may provide a protec-
tion against proteolytic degradation. For targeting to the ER, the
HA lacking the transmembrane domain (amino acid positions 14
to 530 of HA) was fused to the ER-targeting signal of BiP at the
50-end. Additionally, the cellulose-binding domain (CBD) and an
ER retention motif HDEL were sequentially fused to the C-
terminus of HA as an affinity tag for purification and ER retention,
respectively (Figure 1a). The resulting fusion construct, BiP:HA:
CBD:HDEL, was used to generate transgenic plants (HA-TG) and
its expression levels were examined in T4 or T5 generations. Total
protein extracts were analysed by Western blotting using anti-
CBD and anti-H5 antibodies. The BiP:HA:CBD:HDEL protein level
calculated from the band intensity was 700 lg/g in the dried leaf
powders (140 lg/g in fresh leaf tissues) of HA-TG plants in both
generations (Figure 1b). By contrast, no visible band was detected
in protein extracts of wild-type plants with these antibodies,
confirming the specificity of the antibody we used.
Next, we examined its localization by immunostaining. Pro-
toplasts from the transgenic plants at T4 or T5 generation were
immunostained using the CBD antibody. Both samples produced
a network pattern (Figure 1c), indicating that BiP:HA:CBD:HDEL
localizes to the ER. To confirm the ER localization of BiP:HA:CBD:
HDEL at the biochemical level, we examined its glycosylation
pattern. Sequence analysis revealed that the HA contains multiple
N-glycosylation sites (Das et al., 2010). Protein extracts from the
transgenic plants were treated with endoglycosidase H (Endo H)
and analysed by Western blot analysis using anti-CBD and anti-
H5 antibodies. Endo H is an endoglycosidase which cleaves
asparagine (N)-linked mannose-rich oligosaccharides. The CBD-
positive band migrated faster in Endo H-treated extracts than in
control extracts (Figure 1d), indicating that BiP:HA:CBD:HDEL
(a)
(b)
(c)
(d)
Figure 1 HA fusion proteins targeted to the ER
of Arabidopsis shows a high-level accumulation
and N-glycosylation. (a) Schematic representation
of the BiP:HA:CBD:HDEL construct. 35S,
cauliflower mosaic virus 35S promoter; BiP, the
leader sequence of BiP; HA (H5N1),
haemagglutinin of Influenza A virus [A/Hong
Kong/213/2003 (H5N1)]; CBD, cellulose-binding
domain; HDEL, ER retention signal; NOS, nos-
terminator; Km, Kanamycin-resistance gene.
Restriction endonuclease sites used for generating
the construct are indicated. (b) Expression levels of
BiP:HA:CBD:HDEL. Leaf extracts from five
individual plants of T4 or T5 generation of a
transgenic line 19 (HA-TG) and WT plants (WT)
were analysed by Western blotting using anti-CBD
and anti-H5 antibodies. (c) Localization of BiP:HA:
CBD:HDEL in the ER. Protoplasts from leaf tissues
of transgenic plants (T4 or T5 generation) were
immunostained with anti-CBD antibody followed
by FITC-labelled anti-rabbit IgG. (d) N-
glycosylation of BiP:HA:CBD:HDEL. Protein
extracts from leaf tissues were incubated for 1 h
with (+) or without () Endo H and analysed by
Western blotting using anti-CBD and anti-H5
antibodies. Open arrow, glycosylated form; filled
arrow, deglycosylated form.
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was N-glycosylated and the oligosaccharide sidechains are
unprocessed.
To assess whether and to what extent the ER-localized antigen
can withstand the harsh conditions of the gastrointestinal tract,
we examined how much of BiP:HA:CBD:HDEL in freeze-dried leaf
powders of HA-TG remains after treating with pepsin. Suspen-
sions of freeze-dried HA-TG leaf powders and purified HA
(derived from HA-TG) with or without freeze-dried WT leaf
powders were incubated with pepsin at 37 °C for 1 h and
analysed by Western blotting using anti-CBD and anti-H5
antibodies (Figure 2a). The majority (over 60%) of BiP:HA:CBD:
HDEL in the suspension of freeze-dried HA-TG leaf powders
remained intact, while purified HA at both conditions was almost
undetectable, indicating that the ER-localized proteins are
protected against pepsin. Next, we examined stability of the ER-
localized BiP:HA:CBD:HDEL at room temperature (RT) to assess
the long-term stability. After keeping freeze-dried leaf powders of
HA-TG at RT for 1, 2, 4, 8 and 12 months, extracts from these
powders were analysed by Western blotting using anti-CBD and
anti-H5 antibodies (Figure 2b). The BiP:HA:CBD:HDEL level was
maintained nearly at the same level for 1 year at RT, indicating
that BiP:HA:CBD:HDEL proteins are stable in the freeze-dried leaf
powders of HA-TG for a long time at RT.
Humoral immune responses induced by orally
administrated HA-TG plants depend on the type of
adjuvants, antigen doses and immunization schedule
To design an optimal edible vaccination protocol, we initially
screened adjuvants for the induction of an HA-specific immune
response. Cholera toxin (CT), flagellin and saponin are considered
to be potent mucosal adjuvants (Lycke and Holmgren, 1986;
Pickering et al., 2006; Skountzou et al., 2010). Accordingly, mice
were orally administered with 22 mg HA-TG (containing 15 lg of
BiP:HA:CBD:HDEL) together with an adjuvant, CT, recombinant
flagellin (recFLA) or saponin. The amount of BiP:HA:CBD:HDEL
was determined based on a previous study showing that 20 lg of
HA is optimal for oral vaccination (Barackman et al., 2001). As
(a)
(b)
Figure 2 BiP:HA:CBD:HDEL localized in the ER shows a higher degree of
resistance to pepsin treatment and long-term stability. (a) Resistance to
pepsin treatment. Suspensions of freeze-dried leaf powders of HA-TG
plants (HA-TG) and purified BiP:HA:CBD:HDEL (Puri-HA) with (Puri-HA/
WT) or without freeze-dried WT leaf powders were incubated with (+) or
without () pepsin for 1 h at 37 °C and analysed by Western blotting
using anti-CBD and anti-H5 antibodies. (b) Long-term stability of BiP:HA:
CBD:HDEL. Protein extracts from TG-HA plants (T5 generation) stored for
the indicated period of time at RT were analysed by Western blotting using
anti-CBD and anti-H5 antibodies. WT plants were included as a negative
control. M, month.
(a)
(b)
(c)
Figure 3 HA-specific antibody response induced by orally administered
HA-TG plants in mice shows strong dependency on the type of adjuvants.
(a) Oral immunization protocol. The types of plants and the amount of
antigens are indicated. In addition, the types of adjuvant and the amount
of adjuvants are indicated. HA-TG, transgenic Arabidopsis plants; WT,
wild-type plants; CT, cholera toxin; recFLA, recombinant flagellin. HA, BiP:
HA:CBD:HDEL. W, week. (b) Induction of HA-specific IgG in mice. Mice
were orally immunized with HA-TG plant (22 mg) together with indicated
adjuvants as in (a). Sera were collected from mice 2 weeks after final
immunization (7W) and HA-specific IgG levels were measured by ELISA.
Each symbol represents a single mouse and horizontal lines indicate the
mean values (n = 4). (c) HA-specific IgG levels in serum. HA-specific IgG
levels in serum were measured by ELISA at the indicated dilution points.
Error bars represent the SEM (n = 4). *P < 0.05; **P < 0.01;
***P < 0.001. Results shown in this figure are representative of two
independent experiments.
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negative controls, mice were given HA-TG without adjuvant or
WT plants (Figure 3a). Mice were immunized five times in a total,
and sera were collected at three different time points to examine
HA-specific antibody responses (Figure 3a). Among the immu-
nized animals, the highest HA-specific IgG response was induced
in the mice fed with HA-TG plus saponin (Figure 3b and c). In
addition, oral administration of HA-TG plus CT- or recFLA-
induced low levels of HA-specific IgG responses, corresponding to
31.6% and 10.2% of that of the saponin group, respectively.
However, neither HA-TG plants nor WT plants alone did not
develop any detectable levels of HA-specific antibody responses
(Figure 3b and c). These results indicate that saponin is most
effective in the induction of the immune response with orally
administered HA-TG plants.
These results (Figure 3) prompted us to define the most
efficient immunization schedule. We designed three different
immunization schedules, Protocol I to III (Figure S1a). Among
these three protocols we tested, Protocol II involving four times of
priming at weekly intervals followed by a one-week break and
two times of boosting at weekly intervals induced the strongest
HA-specific responses (Figure S1b). Next, we determined the
optimal dose of the antigen to elicit the immune responses. Mice
were orally immunized with 12.5, 25 or 50 mg of freeze-dried
leaf powders of HA-TG which contain 10, 20 or 40 lg of BiP:HA:
CBD:HDEL, respectively, together with 2.5 mg of saponin
according to Protocol II. Regardless of the amount of HA-TG, all
mice developed HA-specific IgG antibody responses (Figure 4b).
Of the three different doses we used, 20 lg HA induced the
highest antibody response (Figure 4b). The HA-specific IgG levels
were maintained 2 months after immunization, indicating the
long persistence time of the immune response (Figure 4c). These
results suggest that edible vaccination for AI can be developed
using HA expressed in the ER of plants. To further confirm this,
we examined the immune response in mice fed with WT plants
together with saponin and found no HA-specific antibody
(a)
(b)
(c)
Figure 4 Induction of HA-specific antibody strongly depends on the
amount of orally administered HA-TG plants. (a) Oral immunization
protocol. W, week. (b) Induction of HA-specific antibody. Mice were orally
immunized with 12.5, 25 or 50 mg of HA-TG (containing 10, 20 and
40 lg BiP:HA:CBD:HDEL, respectively) together with saponin (2.5 mg). As
a negative control, mice were administered with PBS. Sera were collected
1 week after priming or 1 week after boosting immunization, and HA-
specific IgG levels were measured by ELISA. HA, BiP:HA:CBD:HDEL. (c)
Time course of HA-specific IgG induction. Sera were collected from mice
fed with PBS, HA-TG alone or HA-TG plus saponin at the indicated time
points. HA-specific IgG levels in serum were measured by ELISA. Results
displayed are mean  SEM (n = 4). **P < 0.01; ***P < 0.001; n.s. not
significant. Data shown in this figure are from one experiment and are
representative of two independent experiments.
(a)
(b)
(c)
Figure 5 Oral immunization of HA-TG plants together with saponin
induces both IgG and IgA antibody responses. (a, b) HA-specific IgG and
IgA levels in sera and BALF. Sera and BALF were collected from mice fed
with PBS, HA-TG alone or HA-TG together with saponin. HA-specific IgG
and IgA antibody titres in serum (a) and BALF (b) were measured by ELISA.
(c) HA-specific IgG1 and IgG2b antibody levels. HA-specific IgG1 and
IgG2b titres were determined by ELISA. Results represent mean  SEM.
*P < 0.05; **P < 0.01; ***P < 0.001. Pooled results from three
independent experiments are shown, each of them obtained from five
mice per group.
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responses (Figure S2a and b), confirming that the HA-specific
responses are induced by HA expressed in transgenic Arabidopsis
plants.
Oral immunization of HA-TG plants together with
saponin elicits both systemic and mucosal immune
responses
To evaluate the nature of immune responses induced by orally
administered HA-TG, the titres of IgG and IgA in serum and
bronchoalveolar lavage (BAL) fluids were analysed 1 week after
the final immunization. HA-specific IgG and IgA antibody titres in
the sera (Figure 5a) and BAL fluids (Figure 5b) were significantly
higher with HA-TG plus saponin than with PBS or HA-TG alone.
Thus, oral immunization of HA-TG plus saponin strongly induced
both systemic and mucosal immune responses.
To further characterize the immune response elicited by HA-TG
together with saponin, the amount of the IgG subclass, IgG1 and
IgG2b, was determined. Both antibody isotypes were greatly
increased in the mice fed with HA-TG together with saponin
compared to mice fed with PBS or HA-TG plants alone (Figure 5c),
indicating that a mixed IgG1/IgG2b subtype response was induced
by oral immunization of HA-TG together with saponin. Further-
more, oral administration of HA-TG together with saponin did not
elicit the IgE response inmice (Figure S3), suggesting the low risk of
inducing allergic response by the treatment.
We further determined the T-cell response in the spleen,
mesenteric LNs and mediastinal LNs. Mice administered orally
with HA-TG plus saponin showed an increase in the number of
IFN-c-producing T cells in response to in vitro HA antigen
restimulation (Figure 6a) and IFN-c production in response to
anti-CD3/28 antibodies stimulation in all lymphoid tissues we
examined (Figure 6b). These results indicate that oral administra-
tion of HA-TG together with saponin elicits strong HA-specific
antibody and T-cell responses.
Oral immunization of HA-TG plus saponin induces
protective immunity against influenza virus challenge
We examined whether the HA-specific antibodies induced by
the oral administration of HA-TG plus saponin confers a
protective immunity against influenza virus infection. Mice
immunized with HA-TG together with or without saponin, WT
plants together with or without saponin, saponin alone or PBS
alone were intranasally infected with a lethal dose of H5N2
avian influenza virus 1 week after the final immunization
(Figure 7a and Figure S4a). Mice were daily monitored for their
mortality and weight loss for 4 weeks (Figure 7b and c). The
mice fed with PBS or HA-TG alone showed a rapid weight loss
and all mice succumbed within 10 (PBS) or at 12 days (HA-TG
alone) after the challenge. In addition, mice fed with saponin
alone and WT plants with or without saponin died in compa-
rable ratio to that of PBS and HA-TG alone groups (Figure S4b).
By contrast, the majority (72%) of mice fed with HA-TG plus
saponin survived. Moreover, after initial loss of body weight up
to 25% until 10 days after viral challenge, the body weight
gradually recovered and reached the prechallenge level by
28 days of postchallenge, indicating that the protection of mice
from lethal influenza infection conferred by oral immunization
of HA-TG plus saponin is resulted from the induction of
immunity against HA. Taken together, these results suggest
that oral vaccination of mice using HA-TG together with
saponin provides for strong protection against a lethal H5N2
avian influenza virus infection.
Oral immunization using HA-TG plants together with
saponin attenuates pulmonary inflammation caused by
H5N2 infection
To further evaluate the vaccination efficacy, we examined lung
inflammation by analysing viral RNA levels in lung, cellular
(a)
(b)
Figure 6 Immunized mice show HA-specific T-
cell responses in the spleen, mesenteric lymph
node and mediastinal lymph node. (a) T-cell
responses in immunized mice. Mice were orally
administered with PBS, HA-TG alone or HA-TG
together with saponin. T cells from spleen,
mesenteric lymph nodes (LN) or mediastinal LN
were restimulated in vitro with recombinant
haemaggulutinin (HK213-HA) for 36 h (37 °C,
5% CO2) and IFN-c-secreting T cells were
calculated by ELISPOT. The number of IFN-c-
secreting T cells is shown as the average number
of spot-forming cells/1 9 106 cells. (b) IFN-c
production in T cells. T cells were restimulated in
vitro with anti-CD3/CD28 antibodies for 48 h
(37 °C, 5% CO2). Supernatants were collected
and assayed for IFN-c production by ELISA. Results
represent mean  SEM (n = 5). *P < 0.05;
**P < 0.01; ***P < 0.001. mLN, mesenteric
lymph node; MedLN, mediastinal LN. Data shown
are from one experiment and are representative of
two independent experiments.
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infiltration into lung and pro-inflammatory cytokines in BAL
fluids in the mice at 6 days postchallenge (Figure 8a). Viral
load, determined by the expression level of H5N2 viral RNA in
the lung, was significantly lower with HA-TG plus saponin than
with PBS or HA-TG alone (Figure 8b). In particular, the viral
RNA was not detected in surviving mice by 28 days postchal-
lenge, indicating the complete clearance of influenza virus in
the mice (Figure 8b). BAL cell count (Figure 8c) showed that an
HPAI H5N2 infection caused severe neutrophilic infiltration into
the lung. In addition, in mice immunized with HA-TG plus
saponin, the cellular infiltration especially, neutrophilic infiltra-
tion, was significantly decreased (Figure 8c). Furthermore, the
levels of pro-inflammatory cytokines such as IFN-c, IL-6 and
MCP-1 that were induced by H5N2 infection were significantly
reduced in mice immunized orally with HA-TG plus saponin
(Figure 8d). On the other hand, the production of anti-
inflammatory cytokine, IL-10, was comparable in all immunized
mice (Figure 8d). These results indicate that oral vaccination of
mice with HA-TG plus saponin leads to amelioration of the
pulmonary inflammation and protection of mice from lethal
influenza infection.
Discussion
In this study, we generated transgenic Arabidopsis plants
expressing HA of HPAI H5N1 in the ER and examined the
possibility as to whether they can be used as an edible vaccine.
Important prerequisites for the successful vaccination included a
high-level accumulation, proper glycosylation and protection of
the antigen proteins (Borges et al., 2010). It has been proposed
that plant cell walls provide protection of proteins against
proteases, which is termed bio-encapsulation. However, this
does not provide full protection to proteins against proteolytic
degradation before the uptake into the mucosal immune system.
An enhanced resistance to proteolytic degradation can be
obtained when proteins are incorporated into biodegradable
particles such as protein bodies which have a surrounding
membrane (Nochi et al., 2007). We used the ER as a storage
place for antigens for the following reasons: the antigen can be
N-glycosylated and the ER membrane may provide additional
protection to proteolytic degradation. Consistent with our
assumption, over 60% of the chimeric HA proteins expressed in
the ER were protected against the pepsin treatment, while the
same protein purified from the transgenic Arabidopsis was
completely digested. In addition, HA proteins in the ER of
transgenic Arabidopsis were N-glycosylated. Plant-expressed gly-
cosylated proteins exhibit higher immunogenicity as compared to
proteins expressed in mammalian cell cultures (Gomord et al.,
2010). Previously, it has been suggested that subcellular targeting
of foreign proteins to appropriate organelles is a strategy to
increase the protein yield in transgenic plants (Streatfield et al.,
2003). Indeed, high-protein expression levels are successfully
achieved by targeting proteins to ER, chloroplasts or apoplasts
(137–300 lg/g in fresh leaf biomass) (Kalthoff et al., 2010;
Maclean et al., 2007). In this study, we achieved the HA
expression level of approximately 700 lg/g (dry weight) or
140 lg/g (fresh leaf) by ER targeting.
Several studies reported the potential efficacy of plant-based
influenza vaccine systems. Among them, HA virus-like particles
made in Nicotiana benthamiana are of promising, as shown by
the positive results of Phase II clinical trial by the conventional
injection method (D’Aoust et al., 2008). In addition, recombinant
influenza haemagglutinin produced in Nicotiana benthamiana by
rapid transient expression technology was tested for vaccinating
mice, rabbits and ferrets by intramuscular (i.m.) injections in
preclinical studies (Shoji et al., 2011). Both groups showed the
great potential for the plant-based system in influenza vaccine.
Here, we add another option for the plant-based influenza
vaccination by oral administration of TG plants.
In this study, we used HA without the transmembrane domain
and designed it to be accumulated in the ER at high levels. Even
though the transmembrane domain is essential for the trimeriza-
tion, which is in turn crucial for the antigenicity (Phan et al.,
2013), we successfully demonstrated that HA without the
transmembrane domain can induce HA-specific immune
responses in mice. In previous studies, HA ectodomain fused
with carrier proteins can elicit immune response (Musiychuk
et al., 2007; Shoji et al., 2009). Thus, it is possible that the high
level of HA in the plant ER may compensate the loss of the
transmembrane domain which is required for HA trimerization.
In vaccination, an immunoenhancer called adjuvant is essential
for inducing high levels of immune responses. Interestingly, of the
three different types of adjuvants (CT, flagellin and saponin) that
(a)
(b)
(c)
Figure 7 Oral immunization of HA-TG plants together with saponin
confers protective immunity against a lethal dose of H5N2 avian influenza
virus infection. (a) Experimental scheme. W, week. (b, c) Survival rate and
body weight change after H5N2 challenge. Mice immunized with PBS,
HA-TG plants or HA-TG plus saponin were infected with H5N2 avian
influenza virus (A/Korea/w81/2005) 1 week after final immunization.
Survival rate (b) and change in the body weight (c) were monitored daily for
28 days after the challenge. Body weights of the examined day were
presented as relative to that prior to challenge. Results shown are as
mean  SEM. **P < 0.01; ***P < 0.001 by log-rank test. Pooled results
from two independent experiments are shown, each of them obtained from
eight mice.
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we used, the strongest immune response was induced with
saponin in our edible vaccine system. CT is one of the most
frequently used potent mucosal adjuvants (Vajdy and Lycke,
1992) and a bacterial flagellin, a ligand of toll-like receptor 5, has
a strong mucosal adjuvant activity (McSorley et al., 2002). It is
possible that saponin increases the permeability of intestinal
epithelial cells, which may allow more efficient antigen uptake
(Pickering et al., 2006; Sjolander and Cox, 1998). Indeed, recent
studies have shown that orally administered saponin enhances
induction of cytokines, in particular, Th1 cytokines (IFN-c) and
antibodies of IgG2a/b/c isotypes, which represent Th1 response in
mice (Sun et al., 2009).
Production of HA-specific IgG antibodies alone can confer a
protection against Influenza infection by neutralizing and
destroying the virus in circulation (Bai et al., 2011; Tamura and
Kurata, 2004). Our vaccination protocol led to induction of HA-
specific IgG1 and IgG2b. The different isotypes of IgG antibodies
have different roles in preventing viral infection. IgG1 antibody, a
Th2-type antibody, mainly contributes to viral neutralization
(Gerhard et al., 1997; Moran et al., 1999). On the other hand,
the Th1-type antibody IgG2b contributes more to clearance of
virus from the host but is less effective in neutralization
(Nimmerjahn and Ravetch, 2005). The mice fed with HA-TG plus
saponin showed strong Th1 responses together with IgG2b
production, which may mediate an important part of the vaccine-
induced protection from influenza infection. IgG antibodies can
be transferred into the mucosal space by FcRn-mediated trans-
cytosis (Kim et al., 2004; Nimmerjahn and Ravetch, 2005).
Indeed, we detected high levels of HA-specific IgG antibody in
both serum and BALF from mice immunized with HA-TG plus
saponin. In addition to IgG antibodies, HA-TG plus saponin-fed
mice also showed a strong IgA response. IgA is secreted into the
mucosal space, thus contributing to inhibition of virus entry into
host cells (Mbawuike et al., 1999; Muramatsu et al., 2014).
Importantly, IgA could be detected in BALF where it encounters
influenza virus first. Furthermore, the vaccination did not evoke
IgE responses which potentially cause anaphylaxis in the host,
which suggests that oral administration of HA-expressing plants
with saponin may be a safer way of immunization.
The primary cause of death by influenza infection is the strong
lung inflammation (Brandes et al., 2013; Van Reeth et al., 2002).
The HA-TG plus saponin vaccination reduced lung inflammation
after influenza challenge; lower cellular infiltration into lung and
pro-inflammatory cytokine production. Concomitant with this
observation, virus mRNA levels were low in the lung of mice fed
with HA-TG plus saponin. As a result, the vaccinated mice are
protected from death.
Birds such as waterfowl are considered as natural reservoir
hosts for most influenza A viruses. Because of their natural
behaviour, it is extremely difficult to prevent the avian host from
spreading the influenza viruses (Webster and Govorkova, 2006).
Previous studies demonstrated that immunization of plant-
derived HA could protect chickens (Kalthoff et al., 2010) and
ferrets (Shoji et al., 2009) against challenge infection when these
animals were immunized i.m. or subcutaneously (s.c.) with HA
purified from plants. In 2006, first plant-made Newcastle disease
virus vaccine for chickens was approved by the US Department of
Agriculture (Ling et al., 2010). It is a purified injectable vaccine
produced from a transgenic tobacco cell-line. Although this
opened the way to the practical use of plant-made vaccine for
poultry, immunizing the huge numbers of animals one by one in
poultry farms or as free-living birds is practically impossible. Thus,
edible vaccination using plants may be a strategy of choice for the
large-scale immunization of animals such as chickens. Both HA-
TG plants and saponin can be easily formulated as chicken feed.
However, further studies are necessary to show that the results
(a) (b)
(c)
(d)
Figure 8 Oral immunization of HA-TG plants
plus saponin attenuates lung inflammation after
H5N2 avian influenza virus infection. (a)
Experimental scheme. Mice were intranasally
challenged with H5N2 influenza virus 1 week
after the final immunization. Lungs and BALF
were collected at 6 days postchallenge. (b) Viral
mRNA level after H5N2 challenge infection. Viral
RNA was detected by real-time reverse
transcription-PCR. Viral RNA levels were
normalized with the endogenous GAPDH
transcript level and expressed as a fold change
compared with control (PBS-fed mice). Each
sample was analysed in duplicate. Naive,
noninfected mice; Surviving, surviving mice
28 days after challenge; N.D. not detected. (c)
Cell populations in the BALF. The number of total
cells (Total), neutrophils (Neu), macrophages
(Mac), lymphocytes (Lym) and eosinophils (Eos) in
the BALF are shown. (d) The concentrations of
cytokines. IFN-c, IL-6, MCP-1 and IL-10 in the
BALF were measured by ELISA. Results represent
mean  SEM (n = 5). *P < 0.05; **P < 0.01;
***P < 0.001; n.s. not significant; N.D. not
detected. Data shown in this figure are
representative of two independent experiments.
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obtained with mice are applicable to birds or poultry that has
different digestive systems from mice.
In summary, we have demonstrated that oral administration of
HA-expressing transgenic Arabidopsis plants with saponin
induces neutralizing antibodies and cellular immune responses,
which can confer protection against a lethal viral infection. In
addition, the mucosal antibody and cellular immune responses
were rapidly expanded upon viral challenge infection, which
results in an inhibition of viral replication and lung inflammatory
cytokine production. Accordingly, we propose that the edible
vaccination employing oral administration of antigen-expressing
plants together with saponin as adjuvant is an attractive method
of future vaccination.
Experimental procedures
Construction of plasmid DNAs
The DNA fragments encoding HA (amino acid positions from 14 to
530) and the cellulose- binding domain (CBD) were PCR-amplified
from the A/Hong Kong/213/03 (H5N1) influenza virus strain or
Clostridium stercorarium, respectively. The sequences of primers
used in this study are listed in Table S1. The ER retention signal
HDEL was included in the primer for CBD amplification. The PCR
products of HA and CBD with HDEL were sequentially ligated into
the 326-BiP vector, which contains the leader sequence of binding
protein (BiP) of Arabidopsis (Kim et al., 2001). To generate plant
transformation vector pBI121-BiP:HA:CBD:HDEL, BiP:HA:CBD:
HDEL was ligated into the binary vector pBI121 (Clontech). All
PCR products were sequenced to confirm product accuracy.
Generation of transgenic plants
To generate stable transgenic plants, the binary construct,
pBI121-BiP:HA:CBD:HDEL, was transformed into Arabidopsis
plants (ecotype Columbia-0) by the floral dipping method
(Clough and Bent, 1998). Transgenic plants were screened on
1/2 Murashige and Skoog medium supplemented with kanamy-
cin (50 mg/L). Homozygous lines were isolated at T3 generation.
Growth of plants
Transgenic plants were cultivated on Gamborg B5 plates supple-
mented with 1% sucrose at 20–22 °C in a growth chamber with
70% relative humidity under a 16/8-h light/dark cycle. Leaf or
whole tissues were harvested from 2- to 3-week-old plants and
used immediately for protoplast isolation or protein extraction.
For oral immunization, transgenic plants were grown on soil and
healthy leaves harvested from 4-week-old transgenic Arabidopsis
were freeze-dried for 24 h using Freeze Dry Systems (Labconco,
Kansas City, MO). Dried leaf materials were ground to fine
powder using a mortar and pestle and stored at room temper-
ature.
Immunocytochemical analysis
To determine the localization of BiP:HA:CBD:HDEL, protoplasts
from T4 or T5 transgenic Arabidopsis leaf tissues were immuno-
stained with anti-CBD antibody followed by fluorescein isothio-
cyanate (FITC)-conjugated anti-Rabbit IgG as described previously
(Park et al., 2005). Images were captured using a Zeiss LSM 510
META laser scanning confocal microscope in a multitrack mode.
Excitation/emission wavelengths were 488/505–530 nm for FITC.
The data were processed using Adobe Photoshop software
(Adobe Systems, Mountain View, CA), and the images were
rendered in pseudocolour (Jin et al., 2001).
Western blot analysis
Leaf tissues were homogenized by adding denaturation buffer
[1% SDS, 2% (v/v) b-mercaptoethanol], and the extracts were
separated by 10% SDS-PAGE. Western blot analysis was per-
formed using rabbit anti-CBD (a 1 : 5000 dilution, prepared in
our laboratory) and rabbit anti-H5N1 haemagglutinin polyclonal
antibodies (a 1 : 1000 dilution, Bioss, Inc.) as described previously
(Kim et al., 2014). The blot was developed with the enhanced
chemiluminescence kit (Amersham Pharmacia Biotech, Piscat-
away, NJ), and images were captured using the LAS3000 system
(Fujifilm, Tokyo, Japan).
Quantification of HA protein levels in transgenic
Arabidopsis plants
Protein extracts were prepared from the fresh-leaf tissues or fine
power of dried leaf tissues using extraction buffer [100 mM NaCl,
10 mM EDTA, 200 mM Tris–HCl, pH 8.0, 0.1% SDS, 200 mM
Sucrose, 0.05% Tween20, 14 mM b-mercaptoethanol and a
protease inhibitor cocktail]. The homogenates were centrifuged
at 19 000 g for 20 min at 4 °C, and the resulting supernatants
(total soluble protein, TSP) were collected and stored at 20 °C
until analysed. The TSP was quantified by Bio-Rad protein assay
with BSA standards following the manufacturer’s protocol. To
determine the expression level of HA fusion proteins, protein
extracts from HA-TG together with various amount of purified
GFP/CBD fusion proteins (10, 50 and 100 ng) as reference
standard were analysed by Western blotting using anti-CBD
antibody. The signal intensity of bands was measured using Multi
Gauge (V3.0) software (Fujifilm) as described previously (Liu et al.,
2014; Verma et al., 2008).
Purification of HA from transgenic Arabidopsis
Fresh leaves harvested from 3-week-old transgenic Arabidopsis
were homogenized in buffer (10 mM HEPES, pH 7.5, 10 mM NaCl,
3 mM MgCl2, 5 mM EGTA, 5 mM EDTA, 5 mM DTT, 0.2% triton
X-100). The homogenates were centrifuged at 19 000 g for
10 min at 4 °C and the resulting supernatants were loaded on a
column prepared with cellulose (Sigma type 20) and washed with
washing buffer (10 mM HEPES, pH 7.5, 10 mM NaCl, 3 mM
MgCl2, 5 mM EGTA, 5 mM EDTA, 5 mM DTT). Cellulose-bound
BiP:HA:CBD:HDEL proteins were eluted with buffer (1% cellobi-
ose, 10 mM HEPES, pH 7.5, 10 mM NaCl, 3 mM MgCl2, 5 mM
EGTA, 5 mM EDTA). Purified proteins were analysed by Western
blotting using anti-CBD antibody.
Endo H and pepsin treatments
The protein extracts were incubated with Endo H (Roche) for 1 h
at 37 °C and analysed by Western blotting using anti-CBD and
anti-H5 antibodies (Lee et al., 2011). The pepsin treatment was
performed as described previously (Nochi et al., 2007).
Oral immunization and sample collection
Wild-type C57BL/6 (B6) mice (Jackson Laboratories, Bar Harbor,
ME) were maintained under pathogen-free conditions. All exper-
iments were performed in accordance with the guideline of the
Institutional Animal Care Committee of POSTECH. For all exper-
iments, 6–8 weeks old female B6 mice were used.
Mice were orally administered with freeze-dried plant tissues
[suspended in PBS (22 mg/350 lL) of different volume depending
on the vaccine protocols] with or without adjuvants [cholera toxin
(List Biological Laboratories, Inc., Campbell, CA), 10 lg; recFLA
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(Invivogen, San Diego, CA), 50 ng; purified saponin from Quillaja
Bark (Sapogenin content, 20–35%) (Sigma, St. Louis, MO),
2.5 mg] in a total of six times at one-week interval using feeding
needle (Fuchigami). As controls, mice were given WT plants with
or without saponin, saponin alone or PBS alone.
Bronchoalveolar lavage fluids (BALF) were obtained 1 week
after the final immunizations (Kim et al., 2007). Serum and BALF
were centrifuged, and the supernatants were stored at 20 °C.
Spleen, mesenteric lymph nodes and mediastinal lymph nodes
were immediately removed after sacrifice and lymphocytes were
collected for in vitro T-cell proliferation assay.
Intranasal challenge infection
For influenza challenge, 1 week after the final vaccination, mice
were anesthetized by intraperitoneal (IP) injection of ketamine
(100 mg/kg) and xylazine hydrochloride (10 mg/kg) in PBS and
intranasally challenged with two 50% lethal dose (LD50) of H5N2
avian influenza virus (A/Korea/w81/2005, H5N2 that had HA with
93% amino acid sequence identity to HA of H5N1 we used in this
study) as previously described (Park et al., 2009). Mice were daily
monitored for death and weigh loss for 28 days. Sera and BALF
were collected from survived mice at 28 days after challenge.
Lungs were removed for viral RNA isolation. In some experiments,
mice were euthanized on day 3 or 6 postchellenge and sera, BALF
and lungs were collected.
ELISA
HA-specific antibody responses in sera and BALF were measured
by direct enzyme-linked immunosorbent assay (ELISA) (Park et al.,
2009). Purified Influenza A Virus H5N1 HA (A/Hong Kong/213/03)
protein (Sino Biological Inc., Beijing, China) was used to capture
antigen. HRP-conjugated polyvalent goat anti-mouse IgG, IgG1,
IgG2b and IgA (Southern Biotechnology, Birmingham, AL) were
used as the detection antibodies. Total IgE concentration in serum
was determined using the Mouse IgE ELISA Quantitation Set
(Bethyl Laboratories, Montgomery, TX) according to the manu-
facturer’s instructions.
The levels of IFN-c, IL-6, MCP-1 and IL-10 in BALF were
measured by ELISA with mouse ELISA Ready-SET-Go for IFN-c
and IL-10 (eBioscience, San Diego, CA) and Duoset ELISA mouse
kit for IL-6 and MCP-1 (R&D Systems, Minneapolis, MN), in
accordance with manufacturer’s instructions.
Measurement of cytokine production by T cells
The number of IFN-c producing cells in response to in vitro HA
antigen restimulation and IFN-c production in response to anti-
CD3/28 antibodies stimulation in spleens, mesenteric lymph
nodes (mLNs) and mediastinal lymph nodes (MedLNs) were
analysed by ELISPOT or ELISA assay, respectively. Immunized mice
were sacrificed 1 week after the final vaccination and their
spleens, mLNs and MedLNs were removed and homogenized into
single-cell suspensions (Park et al., 2009). Cells isolated from
spleens, mLNs and MedLNs were resuspended in complete RPMI
1640 medium containing 10% FCS, HEPES (20 mM), penicillin
(1000 U/mL), streptomycin (1000 lg/mL), L-Glutamate (2 mM).
Red blood cells were lysed using ACK buffer. For ELISPOT assay,
1 9 106 cells were plated in Multiscreen plates (MSHAN 4510;
Millipore, Burlington, MA) coated with purified rat anti-mouse
IFN-c antibody (BD Pharmingen, San Jose, CA) and cultured in the
complete medium containing influenza A/Hong Kong/213/03 HA
antigen (5 lg/mL) as stimulator, PMA (50 ng/mL)/ionomycine
(750 ng/mL) as positive control or medium alone as negative
control for 36 h. Spots were counted using a dissection micro-
scope. For cytokine measurements, 2 9 105 cells were incubated
with anti-CD3 (5 lg/mL) plus anti-CD28 (2 lg/mL) antibodies for
48 h at 37 °C in 5% CO2. The levels of IFN-c in cell culture
supernatants were measured by Ready-SET-Go ELISA kit (eBio-
science), according to the manufacturers’ instructions.
BAL cell counts
The pellet of the centrifuged BAL fluid was resuspended in PBS,
and the total number of inflammatory cells was counted with a
hemocytometer. After Diff-Quick staining (Dade Behring, Inc.,
Newark, DE) of the BAL cells prepared by cytospin, the types of
inflammatory cells including neutrophils, macrophages, lympho-
cytes or eosinophils, were classified by counting 300 cells and the
percentages of each cell type were calculated.
Real-time reverse transcription-PCR for detection of
virus RNA
Total RNA was extracted from lung tissues using Trizol (Life
Technologies, Carlsbad, CA). cDNA was synthesized using
random primers and GoScript Reverse Transcription System
(Promega, Madison, WI) according to the manufacturer’s instruc-
tions. RT-PCR was conducted using specific primer pairs
(TGCGGGAAAGCAGATAGTGG and TCAGTTAGGTAGCGC-
GAAGC) for H5N2 influenza virus. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as the internal control. The
PCR conditions were followed by Applied Biosystems 7500 FAST
Real-Time PCR System.
Statistical analysis
The unpaired two-tailed Student’s t-test or log-rank test was
performed to analyse the significance in the difference between
samples. All statistical analyses were done with Prism 5 software
(GraphPad, San Diego, CA) and P values <0.05 were considered
statistically significant.
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